ABSTRACT
Background: Covid-19 is a life-threatening disease-causing and accompanying multiple organ injuries in hospitalized patients. Case presentation: A 73-year-old male patient was admitted to a hospital in Tehran province. He had symptoms of COVID-19 disease, and his involvement with COVID-19 was confirmed by the molecular method and patchy areas of ground-glass opacities in the computed tomography (CT) scan. He was under treatment for his diabetes and hypertension. After a few hours of admission, he had low oxygen saturation (80%);hence he became under intensive care, oxygen, and anticoagulant therapy. On day 6 of ICU admission, his clinical status became worse when he had left side pain, hematuria, glucosuria, proteinuria, and high serum creatinine level (3.28 mg/dL). CT scan imaging was indicating of renal hematoma. The surgical or any invasive intervention was impossible due to the unstable status of the patient. Packed red cell and plasma replacement therapy were not effective in the prevention of expiration of the patient on day 7 of hospitalization. Spontaneous renal hemorrhage concurrent with COVID-19 disease was the defmite diagnosis for this case. Conclusion: We think that COVID-19 involvement may accelerate renal injury in our case. Anyhow, there were multiple predisposing risk factors for renal hematoma, in this case, such as diabetes, anticoagulant therapy, and COVID-19. We suggest that COVID-19 involvement accelerates renal problems. Nevertheless, this conclusion should be confirmed by other reports and research by clinical scientists.
ABSTRACT
Background Studies have shown that morbidity and mortality critically increase from COVID-19 in patients with Alzheimer's disease and dementia. But we had an Alzheimer's disease patient treated rapidly from COVID-19 involvement. We explore the probable cause of treatment using in-silico drug screening tools. Case presentation We present an 81-year-old female patient who recovered from COVID-19 disease despite her severe dementia and Alzheimer's disease, and unfavorable respiratory status. The patient was under medical care for ten days. She received standard COVID-19 medical care plus her drugs for Alzheimer's disease. We found those drugs administered for Alzheimer's disease can interact, and probably inhibit, SARS-COV-2 main protease that plays a central role in virus replication. Conclusion Our patient remediated from COVID-19 very well despite being at a higher risk of morbidity and mortality. However, her amnesia may help her to fight and resist respiratory distress. In addition, administered drugs for Alzheimer's disease may interact with viral biomolecules and dwindle SARS-COV-2 replication.